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ABSTRACT 
Background. Tisotumab vedotin (TV; HuMax-TF-ADC), is a first-in-class antibody-drug 
conjugate directed against tissue factor (TF), which is expressed across multiple solid 
tumor types and is associated with poor clinical outcomes. We hypothesize that TV 
could have antitumor activity in tumors known to express TF.  
Methods. This is a phase 1/2 open-label, dose-escalation and -expansion study 
(innovaTV201; NCT02001623) evaluating the safety, tolerability, pharmacokinetics (PK) 
profile, and antitumor activity of TV in patients with locally advanced and/or metastatic 
solid tumors known to express TF. In the dose-escalation phase, patients were treated 
with TV intravenously once every 3 weeks in a traditional 3 + 3 design to determine the 
maximum-tolerated dose (MTD) and recommended phase 2 dose (RP2D). Plasma was 
collected to characterize the PK profile of TV. In the dose-expansion phase, patients are 
treated at the RP2D in seven advanced solid tumor-type cohorts, including bladder, 
cervix, endometrium, esophagus, lung, ovary, and prostate cancers.  
Findings. In the dose-escalation phase, 27 patients with advanced solid tumors 
received TV in eight sequential dose cohorts between 0∙3 and 2∙2 mg/kg. Dose-limiting 
toxicities, including grade 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, 
were observed at TV 2∙2 mg/kg. TV at 2∙0 mg/kg was identified as the MTD and the 
RP2D. The PK profile of TV was dose proportional. In the dose-expansion phase, 147 
patients with solid tumors were treated with TV at 2∙0 mg/kg. The most common (≥20%) 
treatment-emergent adverse events (AEs) of any grade included epistaxis, fatigue, 
nausea, alopecia, conjunctivitis, decreased appetite, and constipation. Across tumor 
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types, the confirmed investigator-assessed overall response rate was 15∙6% (95% CI: 
10∙2%-22∙5%).  
Interpretation. TV demonstrated a manageable safety profile with encouraging 
preliminary antitumor activity across multiple tumor types, in heavily pretreated patients. 
Based on these data, continued evaluation of this agent is needed.  
Funding. Genmab A/S.  
4 
 
RESEARCH IN CONTEXT 
Evidence before the study 
We performed a search through August 9, 2018 to identify all clinical studies evaluating 
the use tissue factor (TF)-targeting therapeutics in patients with cancer. Our search 
included PubMed and used the following search terms: “tissue factor”, or thromboplastin 
or CD142 AND phase. TF is expressed by multiple solid tumor types and contributes to 
cancer biology by promoting metastasis, tumor growth and tumor angiogenesis, 
suggesting that it may be a potential target for therapeutic intervention. Our search 
revealed that no studies have been published on the safety and activity of TF-targeting 
agents in patients with cancer; although two early phase clinical trials evaluated agents 
in patients with macular degeneration or acute lung injury. 
Added value of this study 
To our knowledge, this is the first study assessing the safety, tolerability, 
pharmacokinetics, and preliminary activity of a TF-targeting agent, tisotumab vedotin 
(TV), in patients with cancer. In this phase 1/2 study, TV demonstrates a manageable 
safety profile and preliminary activity in patients with advanced solid tumors, including 
bladder, cervix, endometrium, esophagus, lung, and ovary. 
Implications of all the available evidence 
The prognosis for patients with advanced solid tumors remains poor and there is an 
unmet need for new treatments to improve outcomes. The present trial confirms the 
feasibility and preliminary clinical utility of tisotumab vedotin, a TF-targeting antibody 
drug conjugate, in patients with locally advanced and/or metastatic solid tumors known 
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to express TF. Further studies are required to confirm this activity and assess the 
patient populations in which TV is most likely to be effective.   
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INTRODUCTION 
Tisotumab vedotin (TV) is a first-in-class antibody-drug conjugate (ADC) that is directed 
against tissue factor (TF) expressed on the cell surface of tumor cells to deliver a 
clinically validated toxic payload to tumors.1 TV is comprised of a fully human 
monoclonal antibody specific for TF conjugated to the microtubule-disrupting agent 
monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker.1  
TF is a transmembrane glycoprotein that functions as the main initiator of the extrinsic 
pathway of blood coagulation.2 Beyond its function in coagulation, TF has cell-signaling 
properties.3,4 In conjunction with protease-activate receptor 2, TF can induce an 
intracellular-signaling cascade that tumors can exploit to promote malignant-cell 
survival, tumor growth, angiogenesis, and metastasis.3,4 The role of TF in cancer 
biology is underscored by its aberrant expression in a broad range of solid tumors, 
including gynecologic and genitourinary tumors, squamous cell carcinoma of the head 
and neck (SCCHN), lung, pancreas, gastrointestinal tract cancers and others.5-11 The 
expression of TF is enhanced in cancer through oncogenic events, such as constitutive 
activation of the MAPK- and PI3K-signaling pathways, epithelial-to-mesenchymal 
transition, hypoxia-induced signaling, and loss of tumor suppressor genes.2,12-14 TF 
expression levels have been associated with poor clinical outcomes and higher 
metastatic potential in multiple solid tumor types.9,15,16 Treatment options for many of 
these solid tumors remain limited and, especially in the context of metastatic and 
refractory disease, are often hampered by poor efficacy and significant drug toxicities. 
There is an urgent unmet medical need for more effective and safe treatment 
alternatives for patients with these types of cancer. Given its differential expression in 
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many cancers as well as its role in cancer biology, TF is a rational target for the 
development of therapeutics to help address this unmet need and improve patient 
outcomes across a broad range of solid tumors. 
The antibody moiety of TV was selected from a panel of monoclonal antibodies based 
on interfering with TF-dependent intracellular signaling but not the procoagulant activity 
of TF.1 Upon binding of TF by TV, the resulting complex is internalized and trafficked to 
the lysosome where the linker is enzymatically cleaved, releasing MMAE within the 
targeted tumor cell.1,17 Then MMAE binds to tubulin and disrupts microtubule 
polymerization, resulting in G2/M cell cycle arrest and apoptosis. As a cell-permeable 
molecule, MMAE can also diffuse into the tumor microenvironment where it might 
induce bystander killing of neighboring dividing cells.1,17 These antitumor effects are 
further enhanced by the capacity of TV to activate innate immune cells.1 The binding of 
TV to FcγRIIIa on adjacent natural killer cells can lead to antibody-dependent cellular 
cytotoxicity of TF-expressing tumor cells.1,18 Additionally, TV has been shown to induce 
immunogenic cell death, which can activate innate and adaptive immune responses to 
tumor antigen. In preclinical studies, TV has demonstrated robust antitumor activity in in 
vitro and in vivo mouse models in multiple solid tumors, including bladder, prostate, 
lung, pancreas, ovarian, and cervical, which demonstrated differential expression of 
TF.1  
These preclinical data led to the conduct of the first-in-human TV clinical trial: innovaTV 
201 (NCT02001623), which evaluated the safety, tolerability, pharmacokinetics, and 
antitumor activity of TV in patients with locally advanced and/or metastatic solid tumors 
known to express TF are presented. The results of this trial are presented herein; 
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cancers known to express TF and with susceptibility to microtubule disrupting agents 
were evaluated. 
 
PATIENTS AND METHODS 
Patient Population 
Eligible patients had locally advanced and/or metastatic cancer of the bladder, cervix, 
endometrium, esophagus, non-small cell lung cancer (NSCLC), ovary, prostate (in 
particular castration-resistant prostate cancer [CRPC]), or squamous cell carcinoma of 
the head and neck (SCCHN) (dose escalation only) who had failed or were not eligible 
to receive the available standard of care. Eligible patients were aged ≥18 years, had a 
life expectancy ≥3 months, acceptable organ function, hematologic and coagulation 
status, Eastern Cooperative Oncology Group performance status of 0 or 1, and 
measurable disease according to Response Evaluation Criteria in Solid Tumors 
(RECIST) version 1∙1.19 
Patients were excluded if they had past or current coagulation defects, ongoing major 
bleeding, on long-term antiplatelet or anticoagulant therapy, clinically significant cardiac 
disease, major surgery within 6 weeks before drug infusion or anticipated during study 
treatment, open biopsy within 7 days before drug infusion, had another malignancy, or 
known infection with HIV, hepatitis B virus, or hepatitis C virus. Patients were also 
excluded if they had received prior therapy with an auristatin derivative, bevacizumab 
within 12 weeks from first study dose, radiotherapy within 28 days from first study dose, 
or any other anticancer therapy within five half-lives before first dose. 
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The Independent Ethics Committee (IEC) or Institutional Review Board (IRB) at each 
study site approved the protocol, and the study was conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice Guidelines. All patients provided 
written informed consent for participation. 
Study Design  
This study was conducted as a phase 1/2, open-label, multicenter, dose-escalation and 
dose-expansion study. The primary objective of this study was to establish the safety 
and tolerability of TV. Secondary objectives were to establish the maximum-tolerated 
dose (MTD) of TV, to define the recommended phase 2 dose (RP2D), to characterize 
the pharmacokinetic (PK) profile of TV, and to assess the antitumor activity of TV.  
The dose-escalation phase of this clinical trial was conducted using a traditional 3 + 3 
design. Patients were enrolled to eight cohorts of TV, ranging from 0.3 to 2.2 mg/kg 
administered intravenously once every 3 weeks (1Q3W). The decision to proceed to the 
next dose-level in the dose-escalation phase was based on the rate of dose-limiting 
toxicities (DLT) observed during the first 21-day treatment cycle. If one of the three 
patients at a given dose developed a DLT, then an additional 3 patients were added at 
the same dose level. If none of the three patients, or one of six, developed a DLT then 
the study continued escalation to the next dose level. The dose level below the dose at 
which 2 or more DLTs within 6 patients was defined as the MTD. During the expansion 
phase, patients were enrolled in tumor-type cohorts and treated with TV at the RP2D. 
Patients were treated for up to four cycles or until disease progression. Patients with 
demonstrated clinical benefit, defined as stable disease or better, had the option to 
continue treatment for an additional eight cycles or until unacceptable toxicity. 
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This report includes data from the completed dose-escalation phase and the ongoing 
(data cutoff February 1, 2018) expansion phase of the innovaTV 201 study.  
Safety Assessments 
Adverse events (AEs) were assessed and reported at each visit according to the 
Common Toxicity Criteria for Adverse Events (CTCAE) version 4∙03. Serious AEs 
(SAEs) were defined as any AE that was fatal or life-threatening, required an extended 
hospitalization, resulted in persistent or significant incapacity/dysfunction, was deemed 
medically important, or led to a congenital anomaly or birth defect. A data-monitoring 
committee (DMC) evaluated safety data during the study. Causality for DLTs was 
assessed by the investigators and sponsor in collaboration with the DMC. 
Response Assessments 
Tumor assessments by computed tomography, or alternatively by magnetic resonance 
imaging in patients allergic to iodine contrast or at the discretion of the investigator were 
performed at screening and every 6 weeks during the study. Tumor response was 
investigator assessed per RECIST version 1∙1 criteria.  
Pharmacokinetics  
Blood samples for PK analysis were collected before and after the infusion at each 
cycle. Additional samples were collected during cycles 1 and 2 on day 1 (2 hours, 5 
hours, and 12 hours after the end of the infusion) and on days 2, 8, and 15. PK 
parameters, including area under the concentration time curve (AUC0-t), maximum 
concentration (Cmax), and time to reach maximum concentration (tmax), were determined 
from the concentration-time data, where feasible, for TV and free MMAE by 
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noncompartmental analysis. The PK parameters were calculated separately for cycle 1 
and cycle 2 of treatment with TV. 
Statistical Analyses  
The sample size of the dose-escalation phase was calculated as a maximum of 48 
patients based on the 3 + 3 design with three to six patients in each dose cohort. The 
estimated sample size for the dose-expansion phase was 169 patients, which had an 
82% power to detect an AE with a 1% incidence.  
The full analysis population is comprised of patients who were exposed to study drug. 
This population was used for evaluation of all endpoints. Safety evaluations and PK 
parameters were summarized descriptively. For the efficacy analysis, the investigator-
assessed objective response rate (ORR) was determined with the corresponding two-
sided 95% exact binomial CI. The Kaplan-Meier (KM) method was used to calculate the 
median months for progression-free survival (PFS) and duration of response (DOR), 
which were presented along the two-sided 95% CI.  
Role of the Funding Source 
The funder designed the study in collaboration with a subgroup of investigators, 
managed the clinical trial database, including oversight of data collection, performed 
statistical analyses, and provided medical writing assistance. The corresponding author 
had full access to all the data in the study and had the final responsibility to submit for 
publication. 
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RESULTS 
Patients 
The dose-escalation phase enrolled 27 patients, with a mixed population of primary 
tumor types. Three patients were included in dose cohorts ranging from 0∙3 to 2∙0 
mg/kg, while six patients were included in the 2∙2-mg/kg dose cohort. The median age 
of patients was 62 (43-73) years. The median number of prior therapies was 3 (1-14). In 
the dose-expansion phase, 147 patients were included across seven tumor-type 
cohorts, including bladder (n=15), cervical (n=34), endometrial (n=14), esophageal 
(n=15), NSCLC (n=15), ovarian (n=36), and prostate (n=18). The median age of 
patients was 59 (21-79) years. The median number of prior therapies across tumor 
types ranged from 1∙5 to 4∙0. Patient characteristics are listed in Table 1. Patient 
enrollment and disposition are illustrated in Figure 1.  
Safety 
In the dose-escalation phase, all 27 patients received ≥1 dose of TV and were 
evaluable for DLTs. Three DLTs were identified in the 2∙2-mg/kg dose cohort, including 
type 2 diabetes mellitus, mucositis, and neutropenic fever, all of which were grade 3. 
Based on these data, the MTD and RP2D were defined as 2∙0 mg/kg. There were three 
deaths reported; none of which were considered related to study drug. Two patients 
included in the 0∙3-mg/kg dose cohort died from disease progression; one patient 
(SCCHN) included in the 0∙6-mg/kg dose cohort died from a pharyngeal tumor 
hemorrhage.  
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In the dose-expansion phase, 147 patients received ≥1 dose of TV and were evaluated 
for safety. The mean (standard deviation; SD) duration of treatment in these patients 
was 14∙5 weeks. Across tumor types, the most commonly (occurring in ≥20% of 
patients) reported treatment-emergent AEs (TEAEs) of any grade were epistaxis 
(69∙4%), fatigue (55∙8%), nausea (52∙4%), alopecia (43∙5%), conjunctivitis (42∙9%), 
decreased appetite (36∙1%), constipation (35∙4%), diarrhea (29∙9%), vomiting (28∙6%), 
peripheral neuropathy (22∙4%), dry eye (21∙8%), and abdominal pain (20∙4%) (Table 2). 
Treatment-emergent grade ≥3 AEs occurred in 56∙5% of patients; 40∙8% were deemed 
related to study drug. The most commonly (occurring in >2% of patients) reported 
treatment-emergent grade ≥3 AEs were fatigue (9∙5%), anemia (5∙4%), abdominal pain 
(4∙1%), hypokalemia (4∙1%), conjunctivitis (3∙4%), hyponatremia (3∙4%), and vomiting 
(3∙4%).  
Treatment-emergent SAEs occurred in 45∙6% of patients; 26∙5% were deemed related 
to study drug. The most common treatment-emergent SAEs (occurring in >2% of 
patients) were vomiting (4∙1%), abdominal pain (3∙4%), and anemia (2∙7%) (Table S2). 
There were six AEs with fatal outcomes in the dose-expansion phase: two patients with 
general physical health deterioration, one with disease progression, one with metastasis 
to the central nervous system, one with esophageal metastatic cancer, and one with 
pneumonia. These events were deemed not related to study drug, with the exception of 
pneumonia, which was possibly related. 
AEs of special interest included bleeding-related events, neuropathy, and ocular events 
(conjunctivitis, ulceration, keratitis, symblepharon). Epistaxis was the most commonly 
reported AE, the majority of which were grade 1 in severity. No grade 4-5 bleeding 
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events were reported in the dose-expansion phase. Neuropathy of any grade occurred 
in 42∙9% of patients with 6∙8% of patients experiencing grade ≥3 neuropathy (Table 
S3). The median (SD) time to onset of neuropathy was 8∙7 (0∙1-26∙4) weeks. In patients 
who experienced neuropathy, 81% (51 of 63 patients) had received prior taxane 
chemotherapy, the most common of which was paclitaxel. At the time of this analysis, 
15∙9% (10 of 63) of neuropathy events had resolved, including seven patients with prior 
taxane, and 84∙1% (53 of 63) of patients had ongoing symptoms, of which 44 patients 
received prior taxane. Ocular events of any grade occurred in 60% of patients, with 
conjunctivitis being the most common. Three percent of patients experienced grade ≥3 
ocular events (Table S4). The study protocol was amended to implement ocular 
preventive measures, including the use of lubricating eye drops throughout the study 
period, steroid eye drops during the first 3 days of each treatment cycle, local ocular 
vasoconstrictor use before infusion, and cooling eye masks worn during treatment 
infusion, as well as stricter dose adjustment guidance. These mitigation strategies 
substantially reduced the incidence of conjunctivitis, which decreased from 55∙8% to 
28∙6% (Table S4). 
Pharmacokinetics and Blood Coagulation Parameters  
The PK profile of TV was assessed in the dose-escalation phase. The profiles of mean 
blood concentration for TV and free MMAE are presented in Figure S1. Increases in 
exposure to TV and free MMAE were proportional to dose. The Cmax of TV occurred 
shortly after the end of infusion, whereas levels of free MMAE peaked 1-2 weeks 
following infusion. Only low levels of free MMAE were detected in the systemic 
circulation. Parameters reflecting exposure, including Cmax and AUC0-t, increased 
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proportionally over the dose ranges examined (Table S5). When TV was dosed at 2∙0 
mg/kg (n=3), the mean Cmax value was 1256∙4 µg/mL and the mean AUC0-t value was 
32∙3 h·µg/mL. Following a single-dose administration of TV at 2∙0 mg/kg, time-to-peak 
plasma concentration (tmax) was observed 1∙2 hours from the start of the infusion.  
Blood coagulation parameters, including prothrombin time (PT) and activated partial 
thromboplastin time (aPTT), were not altered by treatment with TV. Across dose-
escalation cohorts, the mean (SD) PT value at baseline was 11∙5 (1∙3) seconds (n=18) 
compared with 11∙7 (1∙5) seconds (n=17) at study completion, while the mean (SD) 
aPTT value at baseline was 28.2 (3∙3) seconds (n=25) compared with 27∙1 (3.2) 
seconds (n=23) at study completion. 
Efficacy 
In the dose-escalation phase, 26 of the 27 patients were evaluable for response, with 
one patient with metastatic cervical cancer achieving a partial response (antitumor 
activity reported in Table S6). This patient had received two prior treatment lines before 
study entry and received TV at 1∙2 mg/kg. In the dose-expansion phase, 128 of 147 
patients were evaluable for investigator-assessed response. Nineteen patients were 
excluded because they did not have at least one on-study response evaluation. Across 
tumor types, the confirmed ORR for the full analysis population was 15∙6% (95% CI: 
10∙2%-22∙5%; 23 of 147 patients). All responses were partial. For each tumor type, the 
ORR was 26∙7% (95% CI: 7∙8%-55∙1%) in bladder, 26∙5% (95% CI: 12∙9%-44∙4%) in 
cervical, 13∙3% (95% CI: 1∙7%-40∙4%) in esophageal, 13∙9% (95% CI: 4∙7%-29∙5%) in 
ovarian, 13∙3% (95% CI: 1∙7%-40∙5%) in NSCLC, 7∙1% (95% CI: 0∙2%-33∙9%) in 
endometrium, and 0 in prostate (Table 3). At 12 weeks, the disease control rate (SD or 
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better) for all evaluable patients was 26∙5% (95% CI: TBD%; 39 of 147 patients). 
Maximum percentage change in tumor size for each dose-expansion cohort is shown in 
Figure 2. Across tumor types, the median confirmed DOR was 5∙7 (3∙0-9∙5) months and 
the median PFS was 3∙0 (2∙8-4∙1) months.  
 
DISCUSSION 
This multicenter, first-in-human clinical trial has validated the targeting of TF for the 
treatment of advanced cancer for the first time, and has shown that TV has an important 
antitumor activity in heavily pretreated patients with multiple different tumors known to 
express TF. The safety profile of TV 2∙0 mg/kg 1Q3W was generally consistent with 
other MMAE-based ADCs, although epistaxis and conjunctivitis were reported at 
increased incidences with TV. Ocular toxicities have been reported with ADCs that 
include ravtansine (DM4) and monomethyl auristatin F (MMAF); however, they are 
rarely described for ADCs that utilize MMAE.20 An ocular mitigation plan was 
implemented during the study that reduced the frequency and severity of ocular AEs, 
including conjunctivitis. Similar ocular mitigation strategies have been used 
prophylactically with other ADCs to manage ocular events. Peripheral neuropathy, a 
known toxicity of MMAE-based ADCs, was observed in patients treated with TV; 
however, most events reported were mild to moderate in severity. Three DLTs were 
reported in the 2∙2-mg/kg dose cohort of the dose-escalation phase, one of which was 
type 2 diabetes mellitus. Hyperglycemia has been previously described as a DLT in 
other MMAE-based ADCs, such as brentuximab vedotin and DMOT4039A, and is likely 
to be due to the cytotoxic payload.21,22 
Commented [CP1]: Note: to be updated  
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This trial validates the use of an ADC-based approach to safely target TF, the main 
initiator of the extrinsic pathway of blood coagulation.2 Coagulation parameters, such as 
PT and aPTT, were not affected by TV administration. Furthermore, despite the 
incidence of grade 1-2 epistaxis in 69∙4% of patients receiving TV, no grade 4-5 
bleeding events were observed in patients in the dose-expansion phase. These findings 
corroborate previous nonclinical toxicology studies of TV in cynomolgus monkeys, 
which demonstrated no significant impact on functional bleeding time or systemic 
parameters of coagulation at doses up to 5 to 6 mg/kg.1  
Although not designed or powered to assess antitumor activity, this trial reports 
encouraging antitumor activity for TV in a broad population of patients with heavily 
pretreated, locally advanced and/or metastatic cancers of the bladder, cervix 
endometrium, esophagus, lung, and ovary. Patients with bladder and cervical cancer 
achieved the highest response rates with TV, with confirmed investigator-assessed 
response rates of 26∙7% and 26∙5%, respectively. Biopsy or archived samples were 
collected at study entry for all patients, and a currently ongoing analysis will assess the 
correlation of tumor TF expression and the antitumor activity of TV. 
These data support the further investigation of TV. Multiple studies are underway, 
including innovaTV 207 and innovaTV 204. The former (NCT03485209) is an ongoing 
phase 2 study evaluating the efficacy, safety, and tolerability of TV monotherapy 
administered every 3 weeks in patients with relapsed, locally advanced or metastatic 
colorectal cancer, NSCLC, pancreatic cancer, or SCCHN.23 The latter (NCT03438396) 
is an ongoing phase 2 study evaluating the efficacy, safety, and tolerability of TV 
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monotherapy in patients with previously treated, recurrent or metastatic cervical cancer 
that had progressed during or after treatment with standard first-line therapy.24 
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FIGURE LEGENDS 
Figure 1. Patient enrollment and disposition in innovaTV 201 (dose escalation and 
expansion) 
 
Figure 2. Maximum reduction in tumor size in the various expansion study cohorts 
recruiting patients with (A) bladder, (B) cervix, (C) endometrium, (D) esophagus, (E) 
NSCLC, (F) ovary, and (G) prostate cancers.  
The black bars indicate tumor size at first scan, and the gray bars indicate best 
response. 
*Persistent nontarget lesions. †Percent change from baseline is 287∙5%.  
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Table 1. Patient Characteristics 
Characteristic Dose Escalation Dose Expansion 
Total patients, No. 27 147 
Age, median (range), y 62 (43-73) 59 (21-79) 
Female, No. (%) 18 (67) 101 (69) 
Race  
White 
Black 
Asian 
Other 
Missing 
27 (100) 
0 
0 
0 
0 
136 (92∙5) 
2 (1∙4) 
4 (2∙7) 
3 (2∙0) 
2 (1∙4) 
ECOG PS, No. (%) 
0 
1 
Missing 
13 (48) 
13 (48) 
1 (4) 
60 (40∙8) 
86 (58∙5) 
1 (0∙7) 
Primary tumor type, No. (%) 
Bladder 
Cervix 
Endometrium 
Esophagus 
NSCLC 
Ovary 
Prostate 
SCCHN 
2 (7) 
2 (7)  
3 (11) 
4 (15) 
4 (15) 
7 (26)  
4 (15) 
1 (4) 
15 (10∙2) 
24 (23∙1) 
14 (9∙5) 
15 (10∙2) 
15 (10∙2)  
36 (24∙5) 
15 (10∙2) 
– 
Number of prior therapies, median (range) 
All 
Bladder 
Cervix 
Endometrium 
Esophagus 
NSCLC 
Ovary 
Prostate 
3 (1-14) 
– 
– 
– 
– 
– 
– 
– 
3 (1-9) 
2 (1-5) 
2 (1-5) 
1.5 (1-5) 
2 (1-4) 
2 (1-5)  
4 (2-9)  
4 (3-7) 
 
Abbreviations: ECOG=Eastern Cooperative Oncology Group; PS=performance status; SCCHN= 
squamous cell carcinoma of the head and neck.  
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Table 2. TEAEs (Occurring in >10% of Patients) in the Dose-Expansion Phase 
Preferred term 
Dose Expansion Phase 
(n=147) 
All 
Grade 
Grade 1 Grade 2 Grade 3 
Any AE, No. (%) 147 
(100∙0) 
146 
(99∙3) 
140 
(95∙2) 
78 (53∙1) 
Epistaxis 102 
(69∙4) 
100 
(68∙0) 
 2 (1∙4) 0 
Fatigue 82 (55∙8) 28 (19∙0) 40 (27∙2) 14 (9∙5) 
Nausea 77 (52∙4) 43 (29∙2) 31 (21∙1)   2 (2∙0) 
Alopecia 64 (43∙5) 23 (15∙6) 41 (27∙9)  0 
Conjunctivitis 63 (42∙9) 21 (14∙3) 37 (25∙2)   5 (3∙4) 
Decreased appetite 53 (36∙1) 34 (23∙1) 17 (11∙6)   2 (1∙4) 
Constipation 52 (35∙4) 34 (23∙1) 16 (10∙9)   2 (1∙4) 
Diarrhea 44 (29∙9) 28 (19∙0) 14 (9∙5)   2 (1∙4) 
Vomiting 42 (28∙6) 26 (17∙7) 11 (7∙5)   5 (3∙4) 
Neuropathy peripheral 33 (22∙4) 24 (16∙3)  7 (4∙8)   2 (1∙4) 
Dry eye 32 (21∙8) 24 (16∙3)  8 (5∙4)  0 
Abdominal pain 30 (20∙4) 12 (8∙2) 12 (8∙2)   6 (4∙1) 
Weight decreased 25 (17∙0)  6 (4∙1) 19 (12∙9)  0 
Dyspnea 24 (16∙3) 12 (8∙2)  9 (6∙1)   2 (1∙4) 
Pruritus 22 (15∙0) 16 (10.9)  6 (4∙1)  0 
Hypokalemia 22 (15∙0) 12 (8∙2)  4 (2∙7)   6 (4∙1) 
Rash 22 (15∙0) 18 (12∙2)  3 (2∙0)   1 (0∙7) 
Myalgia 22 (15∙0) 15 (10∙2)  7 (4∙8)  0 
Arthralgia 21 (14∙3) 12 (8∙2)  9 (6∙1)  0 
Insomnia 21 (14∙3) 14 (9∙5)  6 (4∙1)   1 (0∙7) 
Anemia 20 (13∙6)  4 (2∙7)  8 (5∙4)   8 (5∙4) 
Back pain 19 (12∙9) 11 (7∙5)  7 (4∙8)   1 (0∙7) 
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Cough 18 (12∙2) 16 (10∙9)  2 (1∙4)  0 
Headache 17 (11∙6) 12 (8∙2)  5 (3∙4)  0 
AST increased 17 (11∙6) 10 (6∙8)  6 (4∙1)   1 (0∙7) 
Peripheral sensory 
neuropathy 
16 (10∙9)  8 (5∙4)  5 (3∙4)   3 (2∙0) 
Pyrexia 15 (10∙2) 12 (8∙2)  1 (0∙7)   1 (0∙7) 
ALT increased 15 (10∙2)  6 (4∙1)  7 (4∙8)   2 (1∙4) 
 
*No grade 4-5 events were reported for TEAEs occurring in >10% of patients.  
Abbreviations: AE=adverse event; ALT=alanine aminotransferase; AST=aspartate 
aminotransferase; TEAE=treatment-emergent adverse event. 
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Table 3. Antitumor Activity in the Dose-Expansion Phase 
Response 
Evaluation* 
All 
(n=147) 
Bladder 
(n=15) 
Cervix 
(n=34) 
Endometrium 
(n=14) 
Esophagus 
(n=15) 
NSCLC 
(n=15) 
Ovary 
(n=36) 
Prostate 
(n=12) 
ORR, No. (%)  
(95% CI) 
23 (15∙6) 
(10∙2-22∙5) 
4 (26∙7) 
(7∙8-55∙1) 
9 (26∙5) 
(12∙9-44∙3) 
1 (7∙1) 
(0∙2-33∙9) 
2 (13∙3) 
(1∙7-40∙4) 
2 (13∙3) 
(1∙7-40∙4) 
5 (13∙9) 
(4∙7-29∙5) 
0 
DCR, No. (%) 
(95%CI) 
39 (26∙5) 
(TBD) 
5 (33∙3) 
(TBD) 
15 (44∙1) 
(TBD) 
4 (28∙6) 
(TBD) 
1 (6∙7) 
(TBD) 
2 (13∙3) 
(TBD) 
9 (25∙0) 
(TBD) 
3 (25∙0) 
(TBD) 
 
*Confirmed responses per RECIST, per investigator review. 
Abbreviations: DCR=disease control rate; ORR=overall response rate. 
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Figure 1. Patient enrollment and disposition in innovaTV 201 (dose escalation and 
expansion) 
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Figure 2. Maximum percentage reduction in tumor size in the various expansion study 
cohorts recruiting patients with (A) bladder, (B) cervix, (C) endometrium, (D) esophagus, 
(E) NSCLC, (F) ovary, and (G) prostate cancers. 
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Patient Inclusion and Exclusion Criteria 
Eligible patients had locally advanced and/or metastatic cancer of the bladder, cervix, 
endometrium, esophagus, non-small cell lung cancer, ovary, prostate (in particular 
castration-resistant prostate cancer [CRPC]), or squamous cell carcinoma of the head 
and neck (dose escalation only) who had failed or were not eligible to receive the 
available standard of care. Eligible patients were aged ≥18 years, had a life expectancy 
≥3 months, acceptable organ function, hematologic and coagulation status, Eastern 
Cooperative Oncology Group performance status of 0 or 1, and measurable disease 
according to Response Evaluation Criteria in Solid Tumors version 1∙1.1 However, 
patients with CRPC could be included based on prostate-specific antigen (PSA) and/or 
bone metastases according to the Prostate Cancer Working Group Guideline; and 
patients with ovarian cancer could be included based on CA 125 positivity according to 
the Gynecologic Cancer Intergroup Guideline.2,3  
Patients were excluded if they had past or current coagulation defects, ongoing major 
bleeding, on long-term antiplatelet or anticoagulant therapy, clinically significant cardiac 
disease, major surgery within 6 weeks before drug infusion or anticipated during study 
treatment, open biopsy within 7 days before drug infusion, had another malignancy 
(except for ≤stage 1B cervical carcinoma, prostate cancer with PSA ≤0∙1 ng/mL, breast 
cancer in BRCA1/2+ ovarian cancer patients, noninvasive basal cell or squamous cell 
skin carcinoma, noninvasive superficial bladder cancer, or any curable cancer with 
complete response of >5 years), or known infection with HIV, hepatitis B virus, or 
hepatitis C virus. Patients were also excluded if they had received prior therapy with an 
auristatin derivative, bevacizumab within 12 weeks from first study dose, radiotherapy 
5 
 
within 28 days from first study dose, or any other anticancer therapy within five half-lives 
before first dose. 
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Dose-Limiting Toxicities (DLTs) 
DLTs included the following adverse events (AEs) at least possibly related to TV: 
 Grade 4 neutropenia for minimal duration of 7 days 
 Grade 3 and 4 febrile neutropenia  
 Grade 4 thrombocytopenia  
 Grade 3 thrombocytopenia associated with bleeding episodes 
 Major bleeding  
 Stevens Johnson syndrome, toxic epidermal necrolysis, grade ≥3 cutaneous 
vasculitis 
 Grade 3 neuropathy (not improving to grade 1 within 3 weeks following stop of 
dosing) and grade 4 neuropathy 
 Grade 3 infusion-related AEs that do not resolve to grade 1 or baseline within 24 
hours 
 Grade 4 infusion-related events including anaphylaxis 
 Any grade ≥3 nonhematologic AEs, which occur during the first treatment cycle 
and are at least possibly study drug related, excluding nonhematologic laboratory 
abnormalities that have no clinical consequences and resolve within 48 hours 
 Grade ≥3 diarrhea and/or vomiting persisting for more than 48 hours with optimal 
medical management 
 Grade ≥3 nausea (not disease-related) lasting 3 days or more with optimal 
medical management  
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Patient Recruitment 
Patients were recruited across 3 sites (Denmark [n=1]; United Kingdom [n=1], United 
States [n=1]) for the dose-escalation portion and 21 sites (Belgium [n=6]; Denmark 
[n=2]; Sweden [n=1]; United Kingdom [n=9]; United States [n=3]) for the expansion 
portion.   
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Table S1. Treatment-Emergent SAE (Occurring in >1% of Patients) in the Dose-
Expansion Phase  
Preferred term 
Dose Expansion Phase 
(n=147) 
Any serious AE, No. (%) 67 (45∙6) 
Vomiting 6 (4∙1) 
Abdominal pain 5 (3∙4) 
Anemia 4 (2∙7) 
Hematuria 3 (2∙0) 
Constipation 3 (2∙0) 
Diarrhea 3 (2∙0) 
General physical health deterioration  3 (2∙0) 
Hyponatremia 3 (2∙0) 
Infection 3 (2∙0) 
Malaise 2 (1∙4) 
Vaginal hemorrhage 2 (1∙4) 
Colitis 2 (1∙4) 
Conjunctivitis 2 (1∙4) 
Dysphagia 2 (1∙4) 
Febrile neutropenia 2 (1∙4) 
Hypokalemia 2 (1∙4) 
Lower respiratory tract infection 2 (1∙4) 
Metastases to central nervous system 2 (1∙4) 
Nausea 2 (1∙4) 
Pneumonia 2 (1∙4) 
Sepsis 2 (1∙4) 
Urinary tract infection 2 (1∙4) 
 
Abbreviations: AE=adverse event; SAE=serious adverse event.  
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Table S2. Incidence of Neuropathy AEs in the Dose-Expansion Phase  
Preferred term 
Dose Expansion Phase 
(n=147) 
All Grade Grade ≥3 
Any neuropathy event, No. (%)    63 (42∙9)  10 (6∙8) 
Neuropathy peripheral    33 (22∙4)   2 (1∙4) 
Peripheral sensory neuropathy    16 (10∙9)   3 (2∙0) 
Muscular weakness 12 (8∙2)   1 (0∙7) 
Peripheral motor neuropathy   5 (3.4)   1 (0∙7) 
Paresthesia    4 (2∙7) 0 
Polyneuropathy   4 (2∙7)   2 (1∙4) 
Dysesthesia   3 (2∙0) 0 
Gait disturbance   2 (1∙4) 0 
Hypoesthesia   2 (1∙4) 0 
Demyelinating polyneuropathy    1 (0∙7)   1 (0∙7) 
Guillain-Barré syndrome   1 (0∙7) 0 
Muscular atrophy   1 (0∙7) 0 
 
Abbreviation: AE=adverse event. 
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Table S3. Incidence of Ocular AEs in the Dose-Expansion Phase 
Preferred term 
All Patients (n=147) Before mitigation (n=77) After mitigation (n=70) 
 
All Grade Grade ≥3 Patients AEs, No. Patients AEs, No. 
Any ocular event, No. (%)a 88 (59∙9) 5 (3∙4) 50 (64∙9) 85 38 (54∙3) 79 
Conjunctivitis 63 (42∙9) 5 (3∙4) 43 (55∙8) 59 20 (28∙6) 31 
Dry eye 32 (21∙8) 0 13 (16∙9) 15 19 (27∙1) 20 
Conjunctival ulcer 6 (4∙1) 0 1 (1∙3) 1 5 (7∙1) 5 
Conjunctival hyperemia 4 (2∙7) 0 0 0 4 (5∙7) 5 
Conjunctival scar 4 (2∙7) 0 1 (1∙3) 1 3 (4∙3) 3 
Keratitis  4 (2∙7) 0 1 (1∙3) 2 3 (4∙3) 3 
Noninfective conjunctivitis 4 (2∙7) 0 1 (1∙3) 1 3 (4∙3) 3 
Conjunctival hemorrhage 3 (2∙0) 0 3 (3∙9) 5 0 0 
Symblepharon 3 (2∙0) 0 0 0 3 (4∙3) 3 
Conjunctival disorder 2 (1∙4) 0 0 0 2 (2∙9) 3 
Seasonal allergy 2 (1∙4) 0 1 (1.3) 1 1 (1∙4) 1 
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Conjunctival staining  1 (0∙7) 0 0 0 1 (1∙4) 1 
Conjunctivitis allergic  1 (0∙7) 0 0 0 1 (1∙4) 1 
 
Abbreviation: AE=adverse event. 
aMost patients with conjunctivitis experienced other ocular events.  
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Table S4. PK Parameters of TV by Dose Cohort After a Single Dose 
Dose level 
(mg/kg) 
Patients, 
No. 
AUC
0-t
  C
max
  T
max
  
Mean 
(h·µg/mL) 
CV 
(%) 
Mean 
(µg/mL) 
CV 
(%) 
Mean 
(h) 
CV 
(%) 
0∙3 3 4∙8 12∙4 59∙2 3∙1 1∙5 72∙4 
0∙6 3 12∙2 9∙5 368∙4 8∙2 1∙2 13∙0 
0∙9 3 19∙8 17∙3 601∙9 16∙9 1∙3 11∙8 
1∙2 3 34∙7 18∙5 1084∙7 9∙3 1∙2 11∙7 
1∙5 3 23∙1 21∙1 795∙0 19∙0 1∙1 9∙6 
1∙8 3 35∙4 39∙2 1504∙8 49∙5 1∙2 14∙3 
2∙0 3 32∙3 22∙1 1256∙4 33∙1 1∙2 7∙5 
2∙2 6 55∙5 10∙3 2037∙1 33∙7 1∙1 12∙5 
 
Abbreviations: AUC0-t = area under the concentration time curve; Cmax=maximum concentration; 
CV=coefficient of variation; PK=pharmacokinetic; t
max
=time to reach maximum concentration. 
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Table S5. Antitumor Activity by Dose Cohort in the Dose-Escalation Phase 
Response 
Evaluation* 
All 
Doses 
(n=27) 
0.3 
mg/kg 
(n=3) 
0.6 
mg/kg 
(n=3) 
0.9 
mg/kg 
(n=3) 
1.2 
mg/kg 
(n=3) 
1.5 
mg/kg 
(n=3) 
1.8 
mg/kg 
(n=3) 
2.0 
mg/kg 
(n=3) 
2.2 
mg/kg 
(n=6) 
PR, No. (%) 1 (3∙7) 0 0 0 1 (33∙3) 0 0 0 0 
SD, No. (%) 11 (40∙7) 0 1 (33∙0) 1 (33∙3) 1 (33∙3) 0 3 (100) 1 (33∙3) 4 (66∙7) 
PD, No. (%) 14 (51∙9)  3 (100.0) 1 (33∙0) 2 (66∙7) 1 (33∙3) 3 (100) 0 2 (66∙7) 2 (33∙3) 
NE,
†
 No. (%) 1 (3∙7) 0 1 (33∙0) 0 0 0 0 0 0 
 
*Confirmed responses per RECIST, per investigator review. †Patient died prior to first scan. 
NE=not evaluable; PD=progressive disease; PR=partial response; RECIST= Response Evaluation Criteria in Solid Tumors; SD=stable disease. 
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Figure S1. Mean plasma concentration-time profiles for (A) TV and (B) free MMAE at 
cycles 1 and 2, by dose-escalation cohort 
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